AIMS/HYPOTHESIS: Although the variable number tandem repeat (VNTR) minisatellite 5' to the insulin gene is among the most studied polymorphisms in diabetes, the relationships between VNTR variation, diabetes-related traits and predisposition to type 2 diabetes remain unclear. Since inadequate sample size is likely to have been an obstacle to reliable inference, we examined the relationship between VNTR variation and a range of diabetes-related traits in a cohort of 5,753 Finnish adults. MATERIALS AND METHODS: VNTR genotypes were derived, by typing at the -23HphI variant site, for 5,646 individuals from the Northern Finland Birth Cohort 1966. Associations were sought between these genotypes and a range of anthropometric (BMI, WHR), physiological (blood pressure) and biochemical (fasting glucose, insulin, lipids, indices of insulin sensitivity and beta cell function) measures obtained at clinical examination at 31 years. RESULTS: We found no evidence that VNTR genotype was significantly associated with measures of insulin secretion, insulin sensitivity, glycaemia, adiposity or blood pressure. CONCLUSIONS/ INTERPRETATION: Despite evidence from several relatively small studies suggesting that INS-VNTR genotypes are associated with predisposition to type 2 diabetes, reduced beta cell function and measures of adiposity, the present study failed to detect any association with a range of diabetes-related traits. Taken with other recent studies in large population-based cohorts, these data suggest that previous studies have, at the very least, overestimated the influence of the INS-VNTR on type 2 diabetes-related traits. The effects of INS-VNTR variation on insulin transcription observed in vitro appear not to translate into detectable differences in basal insulin secretion in humans.
AIMS/HYPOTHESIS: Although the variable number tandem repeat (VNTR) minisatellite 5' to the insulin gene is among the most studied polymorphisms in diabetes, the relationships between VNTR variation, diabetes-related traits and predisposition to type 2 diabetes remain unclear. Since inadequate sample size is likely to have been an obstacle to reliable inference, we examined the relationship between VNTR variation and a range of diabetes-related traits in a cohort of 5,753 Finnish adults. MATERIALS AND METHODS: VNTR genotypes were derived, by typing at the -23HphI variant site, for 5,646 individuals from the Northern Finland Birth Cohort 1966. Associations were sought between these genotypes and a range of anthropometric (BMI, WHR), physiological (blood pressure) and biochemical (fasting glucose, insulin, lipids, indices of insulin sensitivity and beta cell function) measures obtained at clinical examination at 31 years. RESULTS: We found no evidence that VNTR genotype was significantly associated with measures of insulin secretion, insulin sensitivity, glycaemia, adiposity or blood pressure. CONCLUSIONS/ INTERPRETATION: Despite evidence from several relatively small studies suggesting that INS-VNTR genotypes are associated with predisposition to type 2 diabetes, reduced beta cell function and measures of adiposity, the present study failed to detect any association with a range of diabetes-related traits. Taken with other recent studies in large population-based cohorts, these data suggest that previous studies have, at the very least, overestimated the influence of the INS-VNTR on type 2 diabetes-related traits. The effects of INS-VNTR variation on insulin transcription observed in vitro appear not to translate into detectable differences in basal insulin secretion in humans.
Authors: John P A Ioannidis; Thomas A Trikalinos; Evangelia E Ntzani; Despina G Contopoulos-Ioannidis Journal: Lancet Date: 2003-02-15 Impact factor: 79.321
Authors: D M Waterworth; S T Bennett; N Gharani; M I McCarthy; S Hague; S Batty; G S Conway; D White; J A Todd; S Franks; R Williamson Journal: Lancet Date: 1997-04-05 Impact factor: 79.321
Authors: M Urbanek; R S Legro; D A Driscoll; R Azziz; D A Ehrmann; R J Norman; J F Strauss; R S Spielman; A Dunaif Journal: Proc Natl Acad Sci U S A Date: 1999-07-20 Impact factor: 11.205
Authors: K Michelmore; K Ong; S Mason; S Bennett; L Perry; M Vessey; A Balen; D Dunger Journal: Clin Endocrinol (Oxf) Date: 2001-10 Impact factor: 3.478
Authors: S Cocozza; G Riccardi; A Monticelli; B Capaldo; S Genovese; V Krogh; E Celentano; E Farinaro; S Varrone; V E Avvedimento Journal: Eur J Clin Invest Date: 1988-12 Impact factor: 4.686
Authors: Rachel M Freathy; Michael N Weedon; Amanda Bennett; Elina Hypponen; Caroline L Relton; Beatrice Knight; Beverley Shields; Kirstie S Parnell; Christopher J Groves; Susan M Ring; Marcus E Pembrey; Yoav Ben-Shlomo; David P Strachan; Chris Power; Marjo-Riitta Jarvelin; Mark I McCarthy; George Davey Smith; Andrew T Hattersley; Timothy M Frayling Journal: Am J Hum Genet Date: 2007-04-23 Impact factor: 11.025
Authors: Elmar W Tobi; P Eline Slagboom; Jenny van Dongen; Dennis Kremer; Aryeh D Stein; Hein Putter; Bastiaan T Heijmans; L H Lumey Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240
Authors: David Melzer; John R B Perry; Dena Hernandez; Anna-Maria Corsi; Kara Stevens; Ian Rafferty; Fulvio Lauretani; Anna Murray; J Raphael Gibbs; Giuseppe Paolisso; Sajjad Rafiq; Javier Simon-Sanchez; Hana Lango; Sonja Scholz; Michael N Weedon; Sampath Arepalli; Neil Rice; Nicole Washecka; Alison Hurst; Angela Britton; William Henley; Joyce van de Leemput; Rongling Li; Anne B Newman; Greg Tranah; Tamara Harris; Vijay Panicker; Colin Dayan; Amanda Bennett; Mark I McCarthy; Aimo Ruokonen; Marjo-Riitta Jarvelin; Jack Guralnik; Stefania Bandinelli; Timothy M Frayling; Andrew Singleton; Luigi Ferrucci Journal: PLoS Genet Date: 2008-05-09 Impact factor: 5.917